Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

G. Deplanque, M. Demarchi, M. Hebbar, P. Flynn, B. Melichar, J. Atkins, E. Nowara, L. Moyé, D. Piquemal, D. Ritter, P. Dubreuil, CD. Mansfield, Y. Acin, A. Moussy, O. Hermine, P. Hammel,

. 2015 ; 26 (6) : 1194-200. [pub] 20150409

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020894

BACKGROUND: Masitinib is a selective oral tyrosine-kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Patients with inoperable, chemotherapy-naïve, PDAC were randomized (1 : 1) to receive gemcitabine (1000 mg/m(2)) in combination with either masitinib (9 mg/kg/day) or a placebo. The primary endpoint was overall survival (OS) in the modified intent-to-treat population. Secondary OS analyses aimed to characterize subgroups with poor survival while receiving single-agent gemcitabine with subsequent evaluation of masitinib therapeutic benefit. These prospectively declared subgroups were based on pharmacogenomic data or a baseline characteristic. RESULTS: Three hundred and fifty-three patients were randomly assigned to receive either masitinib plus gemcitabine (N = 175) or placebo plus gemcitabine (N = 178). Median OS was similar between treatment-arms for the overall population, at respectively, 7.7 and 7.1 months, with a hazard ratio (HR) of 0.89 (95% CI [0.70; 1.13]. Secondary analyses identified two subgroups having a significantly poor survival rate when receiving single-agent gemcitabine; one defined by an overexpression of acyl-CoA oxidase-1 (ACOX1) in blood, and another via a baseline pain intensity threshold (VAS > 20 mm). These subgroups represent a critical unmet medical need as evidenced from median OS of 5.5 months in patients receiving single-agent gemcitabine, and comprise an estimated 63% of patients. A significant treatment effect was observed in these subgroups for masitinib with median OS of 11.7 months in the 'ACOX1' subgroup [HR = 0.23 (0.10; 0.51), P = 0.001], and 8.0 months in the 'pain' subgroup [HR = 0.62 (0.43; 0.89), P = 0.012]. Despite an increased toxicity of the combination as compared with single-agent gemcitabine, side-effects remained manageable. CONCLUSIONS: The present data warrant initiation of a confirmatory study that may support the use of masitinib plus gemcitabine for treatment of PDAC patients with overexpression of ACOX1 or baseline pain (VAS > 20mm). Masitinib's effect in these subgroups is also supported by biological plausibility and evidence of internal clinical validation. TRIAL REGISTRATION: ClinicalTrials.gov:NCT00789633.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020894
003      
CZ-PrNML
005      
20160725112353.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdv133 $2 doi
024    7_
$a 10.1093/annonc/mdv133 $2 doi
035    __
$a (PubMed)25858497
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Deplanque, G $u Department of Medical Oncology, Saint Joseph Hospital, Paris gdeplanque@hpsj.fr.
245    12
$a A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer / $c G. Deplanque, M. Demarchi, M. Hebbar, P. Flynn, B. Melichar, J. Atkins, E. Nowara, L. Moyé, D. Piquemal, D. Ritter, P. Dubreuil, CD. Mansfield, Y. Acin, A. Moussy, O. Hermine, P. Hammel,
520    9_
$a BACKGROUND: Masitinib is a selective oral tyrosine-kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Patients with inoperable, chemotherapy-naïve, PDAC were randomized (1 : 1) to receive gemcitabine (1000 mg/m(2)) in combination with either masitinib (9 mg/kg/day) or a placebo. The primary endpoint was overall survival (OS) in the modified intent-to-treat population. Secondary OS analyses aimed to characterize subgroups with poor survival while receiving single-agent gemcitabine with subsequent evaluation of masitinib therapeutic benefit. These prospectively declared subgroups were based on pharmacogenomic data or a baseline characteristic. RESULTS: Three hundred and fifty-three patients were randomly assigned to receive either masitinib plus gemcitabine (N = 175) or placebo plus gemcitabine (N = 178). Median OS was similar between treatment-arms for the overall population, at respectively, 7.7 and 7.1 months, with a hazard ratio (HR) of 0.89 (95% CI [0.70; 1.13]. Secondary analyses identified two subgroups having a significantly poor survival rate when receiving single-agent gemcitabine; one defined by an overexpression of acyl-CoA oxidase-1 (ACOX1) in blood, and another via a baseline pain intensity threshold (VAS > 20 mm). These subgroups represent a critical unmet medical need as evidenced from median OS of 5.5 months in patients receiving single-agent gemcitabine, and comprise an estimated 63% of patients. A significant treatment effect was observed in these subgroups for masitinib with median OS of 11.7 months in the 'ACOX1' subgroup [HR = 0.23 (0.10; 0.51), P = 0.001], and 8.0 months in the 'pain' subgroup [HR = 0.62 (0.43; 0.89), P = 0.012]. Despite an increased toxicity of the combination as compared with single-agent gemcitabine, side-effects remained manageable. CONCLUSIONS: The present data warrant initiation of a confirmatory study that may support the use of masitinib plus gemcitabine for treatment of PDAC patients with overexpression of ACOX1 or baseline pain (VAS > 20mm). Masitinib's effect in these subgroups is also supported by biological plausibility and evidence of internal clinical validation. TRIAL REGISTRATION: ClinicalTrials.gov:NCT00789633.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové antimetabolity $x škodlivé účinky $x terapeutické užití $7 D000964
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a duktální karcinom slinivky břišní $x farmakoterapie $x enzymologie $x genetika $x mortalita $x patologie $7 D021441
650    _2
$a deoxycytidin $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D003841
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a analýza podle původního léčebného záměru $7 D057194
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a oxidoreduktasy $x genetika $7 D010088
650    _2
$a nádory slinivky břišní $x farmakoterapie $x enzymologie $x genetika $x mortalita $x patologie $7 D010190
650    _2
$a farmakogenetika $7 D010597
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a prospektivní studie $7 D011446
650    _2
$a inhibitory proteinkinas $x škodlivé účinky $x terapeutické užití $7 D047428
650    _2
$a rizikové faktory $7 D012307
650    _2
$a thiazoly $x škodlivé účinky $x terapeutické užití $7 D013844
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Demarchi, M $u Department of Medical Oncology, University Hospital of Besançon, Besançon.
700    1_
$a Hebbar, M $u Department of Medical Oncology, University Hospital, Lille, France.
700    1_
$a Flynn, P $u Metro-Minnesota Community Clinical Oncology Program, Park Nicollet Institute, Minneapolis, USA.
700    1_
$a Melichar, B $u Department of Oncology, Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Atkins, J $u Southeastern Medical Oncology Center, Goldsboro, USA. $7 gn_A_00009772
700    1_
$a Nowara, E $u Department of Clinical and Experimental Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
700    1_
$a Moyé, L $u Department of Biostatistics, University of Texas School of Public Health, Houston, USA.
700    1_
$a Piquemal, D $u Clinical Development, Acobiom, Montpellier.
700    1_
$a Ritter, D $u Clinical Development, Acobiom, Montpellier.
700    1_
$a Dubreuil, P $u Signaling, Hematopoiesis and Mechanism of Oncogenesis, Inserm U1068, CRCM, Marseille Institut Paoli-Calmettes, Marseille Aix-Marseille University, UM 105, Marseille CNRS, UMR7258, CRCM, Marseille Clinical Development, AB Science, Paris.
700    1_
$a Mansfield, C D $u Clinical Development, AB Science, Paris.
700    1_
$a Acin, Y $u Clinical Development, AB Science, Paris. $7 gn_A_00000990
700    1_
$a Moussy, A $u Clinical Development, AB Science, Paris.
700    1_
$a Hermine, O $u Clinical Development, AB Science, Paris Department of Clinical Hematology, Necker Hospital, Paris INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris Paris Descartes - Sorbonne Paris Cité University, Imagine Institute, Paris CNRS ERL 8254, Paris Laboratory of Excellence GR-Ex, Paris National Reference Center on Mastocytosis (CEREMAST), Paris.
700    1_
$a Hammel, P $u Department of Gastroenterology, Hôpital Beaujon, Clichy, France.
773    0_
$w MED00000432 $t Annals of oncology official journal of the European Society for Medical Oncology ESMO $x 1569-8041 $g Roč. 26, č. 6 (2015), s. 1194-200
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25858497 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160725112612 $b ABA008
999    __
$a ok $b bmc $g 1155564 $s 945422
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 26 $c 6 $d 1194-200 $e 20150409 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20160722
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace